Effects of Dulaglutide on Endothelial Progenitor Cells and Arterial Elasticity in Patients with Type 2 Diabetes Mellitus

Overview

Journal Cardiovasc Diabetol

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
Endocrinology

Date 2022 Oct 5

PMID 36199064

Authors

Dandan Xie

Yutong Li

Murong Xu

Xiaotong Zhao

Mingwei Chen

Affiliations

Soon will be listed here.

Abstract

Background: Randomised controlled trial showed that dulaglutide can reduce the risk of atherosclerotic cardiovascular disease (ASCVD) in patients with type 2 diabetes mellitus (T2DM), but the underlying mechanisms remain unclear. This study aimed to investigate the effect of dulaglutide on the number and function of endothelial progenitor cells (EPCs) in the peripheral blood of patients with T2DM and its role in improving arterial elasticity, so as to determine potential mechanisms of preventive effect of dulaglutide on ASCVD.

Methods: Sixty patients with T2DM were treated with 1000 mg/day of metformin and randomly divided into two groups for 12 weeks: metformin monotherapy group (MET group, n = 30), and metformin combined with dulaglutide group (MET-DUL group, n = 30). Before and after treatment, the number of CD34CD133KDR EPCs and the brachial-ankle pulse wave velocity (baPWV) of the participants were measured, and EPC proliferation, adhesion, migration, and tubule formation were assessed in vitro.

Results: There were no significant differences in the number and function of EPCs and baPWV changes in MET group (P > 0.05). In MET-DUL group, nitric oxide (NO) levels and the number of EPCs increased after treatment (P < 0.05), while the levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), advanced glycation end products (AGEs), and baPWV decreased (P < 0.05). EPC proliferation, adhesion, migration, and tubule formation abilities were significantly enhanced (P < 0.05). Correlation analysis showed that in MET-DUL group, the changes in CRP, IL-6, TNF-α, and AGEs were negatively correlated with the number of EPCs and their proliferation and migration abilities (P < 0.05). Body weight, NO, CRP, and IL-6 levels were independent factors affecting the number of EPCs (P < 0.05). The changes in number of EPCs, proliferation and migration abilities of EPCs, and NO and IL-6 levels were independent influencing factors of baPWV changes (P < 0.05).

Conclusion: Dulaglutide can increase the number and function of EPCs in peripheral blood and improve arterial elasticity in patients with T2DM; it is accompanied by weight loss, inflammation reduction, and high NO levels. Dulaglutide regulation of EPCs may be a mechanism of cardiovascular protection.

Citing Articles

Dulaglutide and Dapagliflozin Combination Concurrently Improves the Endothelial Glycocalyx and Vascular and Myocardial Function in Patients with T2DM and Albuminuria vs. DPP-4i.

Korakas E, Thymis J, Oikonomou E, Mourouzis K, Kountouri A, Pliouta L J Clin Med. 2025; 13(24.

PMID: 39768420 PMC: 11678541. DOI: 10.3390/jcm13247497.

Protective effect of Dulaglutide, a GLP1 agonist, on acetic acid-induced ulcerative colitis in rats: involvement of GLP-1, TFF-3, and TGF-β/PI3K/NF-κB signaling pathway.

Mahdy R, Nader M, Helal M, Abu-Risha S, Abdelmageed M Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39579211 DOI: 10.1007/s00210-024-03631-5.

The effect of empagliflozin on circulating endothelial progenitor cells in patients with diabetes and stable coronary artery disease.

Hershenson R, Nardi-Agmon I, Leshem-Lev D, Kornowski R, Eisen A Cardiovasc Diabetol. 2024; 23(1):386.

PMID: 39468546 PMC: 11520434. DOI: 10.1186/s12933-024-02466-x.

Tumoroids, a valid preclinical screening platform for monitoring cancer angiogenesis.

Abbasi-Malati Z, Khanicheragh P, Narmi M, Mardi N, Khosrowshahi N, Hiradfar A Stem Cell Res Ther. 2024; 15(1):267.

PMID: 39183337 PMC: 11346257. DOI: 10.1186/s13287-024-03880-4.

Novel Therapeutics for Type 2 Diabetes Mellitus-A Look at the Past Decade and a Glimpse into the Future.

Chee Y, Dalan R Biomedicines. 2024; 12(7).

PMID: 39061960 PMC: 11274090. DOI: 10.3390/biomedicines12071386.

References

Garg N, Krishan P, Syngle A . Atherosclerosis in Psoriatic Arthritis: A Multiparametric Analysis Using Imaging Technique and Laboratory Markers of Inflammation and Vascular Function. Int J Angiol. 2016; 25(4):222-228. PMC: 5114134. DOI: 10.1055/s-0036-1584918. View

Christen A, Armentano R, Miranda A, Graf S, Santana D, Zocalo Y . Arterial wall structure and dynamics in type 2 diabetes mellitus methodological aspects and pathophysiological findings. Curr Diabetes Rev. 2010; 6(6):367-77. DOI: 10.2174/157339910793499146. View

Yang Z, Xia W, Su C, Wu F, Zhang Y, Xu S . Regular exercise-induced increased number and activity of circulating endothelial progenitor cells attenuates age-related decline in arterial elasticity in healthy men. Int J Cardiol. 2011; 165(2):247-54. DOI: 10.1016/j.ijcard.2011.08.055. View

Gerstein H, Colhoun H, Dagenais G, Diaz R, Lakshmanan M, Pais P . Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394(10193):121-130. DOI: 10.1016/S0140-6736(19)31149-3. View

Ambasta R, Kohli H, Kumar P . Multiple therapeutic effect of endothelial progenitor cell regulated by drugs in diabetes and diabetes related disorder. J Transl Med. 2017; 15(1):185. PMC: 5580204. DOI: 10.1186/s12967-017-1280-y. View

Del Olmo-Garcia M, Merino-Torres J . GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes. J Diabetes Res. 2018; 2018:4020492. PMC: 5902002. DOI: 10.1155/2018/4020492. View

Eriksson L, Saxelin R, Rohl S, Roy J, Caidahl K, Nystrom T . Glucagon-Like Peptide-1 Receptor Activation Does not Affect Re-Endothelialization but Reduces Intimal Hyperplasia via Direct Effects on Smooth Muscle Cells in a Nondiabetic Model of Arterial Injury. J Vasc Res. 2015; 52(1):41-52. DOI: 10.1159/000381097. View

Kim H, Lim W, Seo J, Kim S, Zo Z, Kim M . Prediction of cardiovascular events using brachial-ankle pulse wave velocity in hypertensive patients. J Clin Hypertens (Greenwich). 2020; 22(9):1659-1665. PMC: 8029918. DOI: 10.1111/jch.13992. View

Tu Q, Wang J, Xie H, Zhao Q, Fu J, Xu H . Up-regulation of GLP-1R improved the dysfunction of late EPCs under hyperglycemia by regulating SIRT1 expression. Mol Cell Endocrinol. 2021; 538:111455. DOI: 10.1016/j.mce.2021.111455. View

10.

Dungan K, Tofe Povedano S, Forst T, Gonzalez J, Atisso C, Sealls W . Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014; 384(9951):1349-57. DOI: 10.1016/S0140-6736(14)60976-4. View

11.

Tao J, Wang Y, Yang Z, Tu C, Xu M, Wang J . Circulating endothelial progenitor cell deficiency contributes to impaired arterial elasticity in persons of advancing age. J Hum Hypertens. 2006; 20(7):490-5. DOI: 10.1038/sj.jhh.1001996. View

12.

Fadini G, Mehta A, Dhindsa D, Bonora B, Sreejit G, Nagareddy P . Circulating stem cells and cardiovascular outcomes: from basic science to the clinic. Eur Heart J. 2020; 41(44):4271-4282. PMC: 7825095. DOI: 10.1093/eurheartj/ehz923. View

13.

Mudyanadzo T . Endothelial Progenitor Cells and Cardiovascular Correlates. Cureus. 2018; 10(9):e3342. PMC: 6248662. DOI: 10.7759/cureus.3342. View

14.

Cernes R, Zimlichman R, Shargorodsky M . Arterial elasticity in cardiovascular disease: focus on hypertension, metabolic syndrome and diabetes. Adv Cardiol. 2008; 45:65-81. DOI: 10.1159/000115188. View

15.

Chopra H, Hung M, Kwong D, Zhang C, Pow E . Insights into Endothelial Progenitor Cells: Origin, Classification, Potentials, and Prospects. Stem Cells Int. 2018; 2018:9847015. PMC: 6276490. DOI: 10.1155/2018/9847015. View

16.

Han J, Choi D, Choi S, Kim B, Ki Y, Chung J . Predictive value of brachial-ankle pulse wave velocity for cardiovascular events. Am J Med Sci. 2012; 346(2):92-7. DOI: 10.1097/MAJ.0b013e318268c05a. View

17.

Zhang M, Zhou S, Li X, Shen X, Fang Z . A novel hypothesis of atherosclerosis: EPCs-mediated repair-to-injury. Med Hypotheses. 2007; 70(4):838-41. DOI: 10.1016/j.mehy.2007.06.041. View

18.

Mikirova N, Casciari J, Hunninghake R, Beezley M . Effect of weight reduction on cardiovascular risk factors and CD34-positive cells in circulation. Int J Med Sci. 2011; 8(6):445-52. PMC: 3156990. DOI: 10.7150/ijms.8.445. View

19.

Bastard J, Maachi M, Lagathu C, Kim M, Caron M, Vidal H . Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006; 17(1):4-12. View

20.

Wagenseil J, Ciliberto C, Knutsen R, Levy M, Kovacs A, Mecham R . Reduced vessel elasticity alters cardiovascular structure and function in newborn mice. Circ Res. 2009; 104(10):1217-24. PMC: 2800958. DOI: 10.1161/CIRCRESAHA.108.192054. View